Company told more measures needed to limit damage to patients' eyes caused by antibody drug conjugate.
GlaxoSmithKline plc’s stake in the market for next-generation multiple myeloma treatments looks set to be limited by safety and efficacy concerns about its candidate belantamab mafodotin.
The anti-BCMA antibody-drug conjugate (ADC) has shown promise as a monotherapy or combination therapy for relapsed or refractory multiple myeloma,...
Four Chinese companies have won approvals in China, the first anywhere, for novel drugs for diffuse large B-cell lymphoma, certain types of non-small cell lung cancer and influenza A.
IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.
CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.
